Last 39.90
Change Today -0.50 / -1.24%
Volume 73.8K
XTLB On Other Exchanges
Symbol
Exchange
NASDAQ CM
Tel Aviv
As of 10:24 AM 01/26/15 All times are local (Market data is delayed by at least 15 minutes).

xtl biopharmaceuticals ltd (XTLB) Snapshot

Open
$42.00
Previous Close
$40.40
Day High
$42.00
Day Low
$39.00
52 Week High
04/3/14 - $82.00
52 Week Low
10/21/14 - $31.10
Market Cap
95.0M
Average Volume 10 Days
84.0K
EPS TTM
$-0.01
Shares Outstanding
238.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for XTL BIOPHARMACEUTICALS LTD (XTLB)

Related News

No related news articles were found.

xtl biopharmaceuticals ltd (XTLB) Related Businessweek News

No Related Businessweek News Found

xtl biopharmaceuticals ltd (XTLB) Details

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, is engaged in the acquisition and development of pharmaceutical products for the treatment of unmet medical needs. The company’s lead drug candidate is hCDR1, a Phase II clinical trial product for the treatment of systemic lupus erythematosus related autoimmune process; and recombinant human erythropoietin (rHuEPO) for the treatment of multiple myeloma patients, as well as for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia. Its rHuEPO has also granted an orphan drug designation from the FDA for the treatment of multiple myeloma. The company is also developing SAM-101, a proprietary combination of antipsychotic drugs and a medicinal compound, which has completed Phase IIa clinical trials as a therapy for psychotic diseases with focus on schizophrenia. It has a licensing agreement with Yeda Research and Development Company for the development of hCDR1. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was founded in 1993 and is based in Herzliya, Israel.

12 Employees
Last Reported Date: 04/2/14
Founded in 1993

xtl biopharmaceuticals ltd (XTLB) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

xtl biopharmaceuticals ltd (XTLB) Key Developments

XTL Biopharmaceuticals Ltd. Announces Board Appointments

XTL Biopharmaceuticals Ltd. announced that the company's shareholders approved the appointment of two new members to the Board of Directors, Doron Turgeman and Shlomo Shalev. Turgeman is currently the Chief Executive Officer of B Communications (BCOM) and Internet Gold (IGLD). Shlomo Shalev most recently served as Chairman of the Board of Micronet.

XTL Biopharmaceuticals Ltd. Announces Board Appointments

XTL Biopharmaceuticals Ltd. announced that the Board of Directors has appointed two new members, Dr. Jonathan Schapiro and Dr. Dobroslav Melamed. Dr. Jonathan Schapiro, 54, is currently an Adjunct Clinical Assistant Professor in the Department of Medicine, Division of Infectious Diseases and Geographic Medicine at Stanford University School of Medicine and a Director of HIV/AIDS at the National Hemophilia Center at Sheba Medical Center in Tel Aviv, Israel. He has served as a committee member on the United States Food and Drug Administration Antiviral Drugs Advisory Committee and is a member of the World Health Organization Global HIV Drug Resistance Network Steering Group. Dr. Dobroslav Melamed, 37, is a biotech entrepreneur with over 10 years of experience in the life science industry. He has demonstrated success in taking drugs from the lab to the shelf by identifying target markets, planning regulatory strategy, raising capital, executing successful clinical trials and scaling up to commercial production. He is currently establishing two companies involved in the development of a treatment for Ebola and novel drug delivery.

XTL Biopharmaceuticals Ltd. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

XTL Biopharmaceuticals Ltd. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported revenue was $0.287 million against $0.473 million a year ago. Operating loss was $0.494 million against profit of $0.829 million a year ago. Loss attributable to equity holders of the company was $0.510 million against profit of $0.549 million a year ago. Basic and diluted loss per share was $0.002 against earnings of $0.002 a year ago. Net cash used in operating activities was $0.455 million against $0.758 million a year ago. For the nine months, the company reported revenue was $1.25 million against $1.66 million a year ago. Operating loss was $1.97 million against $1.09 million a year ago. Loss attributable to equity holders of the company was $1.76 million against $1.33 million a year ago. Basic and diluted loss per share was $0.008 against $0.006 a year ago. Net cash used in operating activities was $1.796 million against $1.979 million a year ago. Purchase of property, plant and equipment was $0.010 million against $0.010 million a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
XTLB:IT 39.90 -0.50

XTLB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for XTLB.
View Industry Companies
 

Industry Analysis

XTLB

Industry Average

Valuation XTLB Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact XTL BIOPHARMACEUTICALS LTD, please visit www.xtlbio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.